ΔRDW Could Predict Major Adverse Cardiovascular Events in Patients with Heart Failure with Reduced Ejection Fraction After Sacubitril/Valsartan Treatment

References

• Murphy SP, Ibrahim NE, Januzzi JL. Heart failure with reduced ejection fraction: a review. JAMA. 2020;324(5):488–504. doi:10.1001/jama.2020.10262
   PubMed Web of Science ®Google Scholar
• Wang J, Xiao Q, Li Y. ΔRDW: a novel indicator with predictive value for the diagnosis and treatment of multiple diseases. Int J Gene Med. 2021;14:8667. doi:10.2147/IJGM.S339945
   PubMed Web of Science ®Google Scholar
• He W, Jia J, Chen J, et al. Comparison of prognostic value of red cell distribution width and NT-proBNP for short-term clinical outcomes in acute heart failure patients. Int Heart J. 2014;56(1):13–172. doi:10.1536/ihj.14-136
   PubMedGoogle Scholar
• Guo B-F, Sun S-Z. Diagnostic accuracy of a dynamically increased red blood cell distribution width in very low birth weight infants with serious bacterial infection. Ital J Pediatr. 2021;47(1):1–7. doi:10.1186/s13052-021-00994-w
   PubMed Web of Science ®Google Scholar
• Lee SI, Lee SY, Choi CH, et al. Relation between changes in red blood cell distribution width after coronary artery bypass grafting and early postoperative morbidity. J Thoracic Dis. 2018;10(7):4244. doi:10.21037/jtd.2018.06.108
   PubMed Web of Science ®Google Scholar
• Ebata S, Yoshizaki A, Fukasawa T, et al. Increased red blood cell distribution width in the first year after diagnosis predicts worsening of systemic sclerosis-associated interstitial lung disease at 5 years: a pilot study. Diagnostics. 2021;11(12):2274. doi:10.3390/diagnostics11122274
   Web of Science ®Google Scholar
• Habibpour H, Torabi M, Mirzaee M. The value of red cell distribution width (RDW) and trauma-associated severe hemorrhage (TASH) in predicting hospital mortality in multiple trauma patients. Bull Emerg Trauma. 2019;7(1):55. doi:10.29252/beat-070108
   PubMedGoogle Scholar
• Ferreira JP, Girerd N, Arrigo M, et al. Enlarging red blood cell distribution width during hospitalization identifies a very high-risk subset of acutely decompensated heart failure patients and adds valuable prognostic information on top of hemoconcentration. Medicine. 2016;95(14):e3307. doi:10.1097/MD.0000000000003307
   PubMed Web of Science ®Google Scholar
• Xu M, Yan L, Xu J, et al. Predictors and prognosis for incident in-hospital heart failure in patients with preserved ejection fraction after first acute myocardial infarction: an observational study. Medicine. 2018;16(1):97. doi:10.1186/s12916-018-1080-0
   Google Scholar
• Chang P-C, Lin S-F, Chu Y, et al. LCZ696 therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarction-induced heart failure rat model. Cardiovasc Ther. 2019;2019:1–9. doi:10.1155/2019/6032631
   Google Scholar
• Mochel JP, Teng CH, Peyrou M, et al. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation. Eur J Pharm Sci. 2019;128:103–111. doi:10.1016/j.ejps.2018.11.037
   PubMed Web of Science ®Google Scholar
• Wadell D, Jensen J, Englund E, et al. Triple therapy after PCI–Warfarin treatment quality and bleeding risk. PLoS One. 2018;13(12):e0209187. doi:10.1371/journal.pone.0209187
   PubMed Web of Science ®Google Scholar
• Zheng X, Wu L. The value of cytochrome P4502C19 gene assay for anti-platelet therapy after PCI in stable angina patients with left main coronary artery lesions. J Southern Med Univ. 2020;40(2):274–278. doi:10.12122/j.issn.1673-4254.2020.02.21
   Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF). Eur J Heart Fail. 2013;15(9):1062–1073. doi:10.1093/eurjhf/hft052
   PubMed Web of Science ®Google Scholar
• Wołowiec Ł, Rogowicz D, Banach J, et al. Prognostic significance of red cell distribution width and other red cell parameters in patients with chronic heart failure during two years of follow-up. Kardiol Pol. 2016;74(7):657–664. doi:10.5603/KP.a2016.0004
   PubMed Web of Science ®Google Scholar
• Förhécz Z, Gombos T, Borgulya G, et al. Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. Am Heart J. 2009;158(4):659–666. doi:10.1016/j.ahj.2009.07.024
   PubMed Web of Science ®Google Scholar
• Turcato G, Zorzi E, Prati D, et al. Early in-hospital variation of red blood cell distribution width predicts mortality in patients with acute heart failure. Int J Cardiol. 2017;243:306–310. doi:10.1016/j.ijcard.2017.05.023
   PubMed Web of Science ®Google Scholar
• Slivnick J, Lampert BC. Hypertension and heart failure. Heart Fail Clin. 2019;15(4):531–541. doi:10.1016/j.hfc.2019.06.007
   PubMed Web of Science ®Google Scholar
• Berg DD, Braunwald E, DeVore AD, et al. Efficacy and safety of sacubitril/valsartan by dose level achieved in the PIONEER-HF trial. Heart Failure. 2020;8(10):834–843. doi:10.1016/j.jchf.2020.06.008
   Google Scholar
• Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC. 2018;6(6):489–498. doi:10.1016/j.jchf.2018.02.004
   Google Scholar
• Heyse A, Manhaeghe L, Mahieu E, et al. Sacubitril/valsartan in heart failure and end‐stage renal insufficiency. ESC Heart Fail. 2019;6(6):1331–1333. doi:10.1002/ehf2.12544
   PubMed Web of Science ®Google Scholar
• Neeland IJ, Winders BR, Ayers CR, et al. Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. Journal of the American College of Cardiology. 2013;62(8):752–760. doi:10.1016/j.jacc.2013.03.038
   PubMed Web of Science ®Google Scholar
• Sharma A, Zhao X, Hammill BG, et al. Trends in noncardiovascular comorbidities among patients hospitalized for heart failure: insights from the get with the guidelines–heart failure registry. Circulation. 2018;11(6):e004646. doi:10.1161/CIRCHEARTFAILURE.117.004646
   PubMed Web of Science ®Google Scholar
• Tan Y, Zhang Z, Zheng C, et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17(9):585–607. doi:10.1038/s41569-020-0339-2
   PubMed Web of Science ®Google Scholar
• Kobalava Z, Kotovskaya Y, Averkov O, et al. Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ 696) in patients with heart failure and reduced ejection fraction. Cardiovasc. Ther. 2016;34(4):191–198. doi:10.1111/1755-5922.12183
   PubMed Web of Science ®Google Scholar
• Giamouzis G, Butler J. Glycaemic control in heart failure: a PARADIGM shift for patients with concomitant diabetes? The lancet. Diabetes Endocrinol. 2017;5:314–315.
   PubMed Web of Science ®Google Scholar
• Fredersdorf S, Endemann D, Luchner A, et al. Increased aldosterone levels in a model of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2009;117(01):15–20. doi:10.1055/s-2008-1073128
   PubMedGoogle Scholar
• Wittenbecher C, Eichelmann F, Toledo E, et al. Lipid profiles and heart failure risk: results from two prospective studies. Circ Res. 2021;128(3):309–320. doi:10.1161/CIRCRESAHA.120.317883
   PubMed Web of Science ®Google Scholar
• Lu Y, Xu Z, Georgakis MK, et al. Smoking and heart failure: a Mendelian randomization and mediation analysis. SC Heart Fail. 2021;8(3):1954–1965. doi:10.1002/ehf2.13248
   Google Scholar
• Goldberg IJ, Trent CM, Schulze PC. Lipid metabolism and toxicity in the heart. Cell Metab. 2012;15(6):805–812. doi:10.1016/j.cmet.2012.04.006
   PubMed Web of Science ®Google Scholar
• Halade GV, Kain V, Tourki B, et al. Lipoxygenase drives lipidomic and metabolic reprogramming in ischemic heart failure. Metabolism. 2019;96:22–32. doi:10.1016/j.metabol.2019.04.011
   PubMed Web of Science ®Google Scholar
• Ruiz‐Canela M, Hruby A, Clish CB, et al. Comprehensive metabolomic profiling and incident cardiovascular disease: a systematic review. J Am Heart Assoc. 2017;6:e005705.
   PubMed Web of Science ®Google Scholar
• Guasch-Ferré M, Hruby A, Toledo E, et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care. 2016;39(5):833–846. doi:10.2337/dc15-2251
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Patel K, Nyaku MA, et al. Risk of heart failure and death after prolonged smoking cessation: role of amount and duration of prior smoking. Circulation. 2015;8(4):694–701. doi:10.1161/CIRCHEARTFAILURE.114.001885
   PubMed Web of Science ®Google Scholar
• Nicolozakes AW, Binkley PF, Leier CV. Hemodynamic effects of smoking in congestive heart failure. Am J Med Sci. 1988;296(6):377–380. doi:10.1097/00000441-198812000-00002
   PubMed Web of Science ®Google Scholar